Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

1.1K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.1K
Analgesia and Pain Management01:25

Analgesia and Pain Management

2.7K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
2.7K
Drug Therapy01:28

Drug Therapy

376
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
376
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

723
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
723
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

777
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
777
Management of Insomnia01:19

Management of Insomnia

764
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
764

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Plasma-Derived miRNAs as Fluid Biomarkers to Differentiate Alzheimer's and Frontotemporal Dementia.

Current issues in molecular biology·2026
Same author

Virtual brain and electroencephalography explain the variance of memory alterations in mild cognitive impairment.

Alzheimer's research & therapy·2026
Same author

Advancing high-altitude medicine: a model for the future.

Signal transduction and targeted therapy·2026
Same author

Alterations in topological and dynamical parameters correlate with disease biomarkers and neuropsychological scores in prodromic stages of dementia.

Scientific reports·2026
Same author

Beyond Pain: Psychological Profiles in Chronic Migraine Compared With Fibromyalgia and Their Comorbidity.

Annals of the New York Academy of Sciences·2026
Same author

Reclassifying transcranial pulse stimulation as TNUS: Nonlinear mechanics necessitate departure from the ITRUSST framework.

Brain stimulation·2026

Related Experiment Video

Updated: Mar 19, 2026

Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders
05:49

Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders

Published on: November 1, 2024

1.3K

Recent advances in migraine therapy.

Fabio Antonaci1, Natascia Ghiotto2, Shizheng Wu3

  • 1Headache Center, C. Mondino National Neurological Institute, Pavia, Italy ; Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.

Springerplus
|June 23, 2016
PubMed
Summary

Migraine management requires patient education and optimized acute treatments like triptans. Emerging therapies targeting CGRP and other pathways show promise for future migraine prevention and acute care.

Keywords:
Acute treatmentMigrainePreventive treatment

More Related Videos

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

18.8K
Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache
05:40

Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache

Published on: July 29, 2021

10.1K

Related Experiment Videos

Last Updated: Mar 19, 2026

Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders
05:49

Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders

Published on: November 1, 2024

1.3K
3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

18.8K
Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache
05:40

Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache

Published on: July 29, 2021

10.1K

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Migraine is a prevalent, disabling neurological disorder with significant socioeconomic impact.
  • Effective management relies on patient education and current acute treatments, including specific (ergot derivatives, triptans) and non-specific (NSAIDs) options.

Purpose of the Study:

  • To review emerging pharmacological strategies for acute and preventive migraine treatment.
  • To discuss preclinical and clinical data on novel compounds nearing or in clinical trials.

Main Methods:

  • Review of preclinical and clinical data on novel migraine treatment compounds.
  • Focus on agents targeting calcitonin gene-related peptide (CGRP), serotonin 5-HT1F receptor, nitric oxide synthase, and acid-sensing ion channels.

Main Results:

  • Existing acute therapies can be optimized, but migraine remains a chronic condition.
  • Several novel pharmacological targets and compounds are under investigation for improved migraine management.

Conclusions:

  • Emerging therapies targeting CGRP, serotonin receptors, and other pathways represent promising advancements in migraine treatment.
  • Continued research into novel pharmacological strategies is crucial for addressing the unmet needs in acute and preventive migraine care.